製品の概要

  • 製品名Tolbutamide
  • 製品の詳細
    K+ channel blocker
  • 生理活性の詳細Blocker of ATP-sensitive (KIR6.x) inward rectifier K+ channels.
  • 精製度> 99%

製品の特性

    アプリケーション

    Our Abpromise guarantee covers the use of ab120278 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    アプリケーション Abreviews 特記事項
    Functional Studies Use at an assay dependent concentration.

    Tolbutamide 画像

    • U-87 MG cells were incubated at 37°C for 30 minutes with vehicle control (0 µM) and 200 µM of tolbutamide (ab120278) in DMSO. Increased expression of hexokinase type II (ab70360) correlates with an increase in tolbutamide concentration, as described in literature.

      Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab70360 at 2 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

    Tolbutamide (ab120278) 使用論文

    This product has been referenced in:
    • Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 158 Suppl 1:S1-254 (2009). Read more (PubMed: 19883461) »
    • Kubo Y  et al. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol Rev 57:509-26 (2005). Read more (PubMed: 16382105) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120278.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"